---
title: "Alphamab Oncology's KN035 Accepted For Chinese Regulatory Review"
description: "Alphamab Oncology's KN035 Accepted For Chinese Regulatory Review"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/272214027.md"
published_at: "2026-01-12T03:55:44.000Z"
---

# Alphamab Oncology's KN035 Accepted For Chinese Regulatory Review

### Related Stocks

- [09966.HK - ALPHAMAB-B](https://longbridge.com/en/quote/09966.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Alphamab Oncology Files HKEX Disclosure on 500,000 Share Repurchase at HKD 4.83 Million | Alphamab Oncology has disclosed a share repurchase of 500,000 shares for a total of HKD 4,833,510, as reported to the Ho | [Link](https://longbridge.com/en/news/271193146.md) |
| Alphamab Oncology IND Application for JSKN027 Accepted by Chinese Regulator | Alphamab Oncology's IND application for JSKN027, a PD-L1/VEGFR2 bispecific antibody-drug conjugate, has been accepted by | [Link](https://longbridge.com/en/news/269992020.md) |
| ZAWYA-PRESSR: Emirates Health Platform showcases national efforts to advance health policies and legislation through digital solutions | The Emirates Health platform showcased key projects at the World Health Expo 2026 in Dubai, emphasizing the collaboratio | [Link](https://longbridge.com/en/news/275625609.md) |
| ‘XRP is the North Star for Ripple’: Garlinghouse keeps door open for more M&A in second half of 2026 | Ripple CEO Brad Garlinghouse indicated that while significant acquisitions are unlikely in the near term, he remains ope | [Link](https://longbridge.com/en/news/275646537.md) |
| China’s Zhipu unveils new AI model, jolting race with DeepSeek | Chinese AI developer Zhipu is launching an upgraded model, GLM-5, to compete with DeepSeek's upcoming product. GLM-5, fe | [Link](https://longbridge.com/en/news/275590715.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.